High-density lipoprotein and coronary heart disease: current and future therapies

Area of Science:

• Cardiovascular Medicine
• Lipid Metabolism
• Pharmacology

Background:

• Coronary heart disease (CHD) is a leading cause of death globally, despite advances in managing risk factors like low-density lipoprotein cholesterol (LDL-C).
• Population studies reveal a strong inverse relationship between high-density lipoprotein cholesterol (HDL-C) levels and CHD risk.
• HDL-C is increasingly recognized as a significant therapeutic target for cardiovascular disease prevention.

Purpose of the Study:

• To review the cardioprotective mechanisms of HDL.
• To examine how current and emerging therapies leverage HDL's beneficial properties.
• To provide a biological framework for understanding HDL-targeting treatment strategies, successes, and failures.

Main Methods:

• Literature review of epidemiological studies on HDL-C and CHD risk.
• Analysis of clinical trial data on therapies aimed at increasing HDL-C levels.
• Exploration of the biological functions and pathways influenced by HDL.

Main Results:

• Epidemiological data consistently support an inverse association between HDL-C and CHD risk.
• Initial clinical trials suggest potential benefits of raising HDL-C, but outcomes are pending larger studies.
• Understanding HDL's protective mechanisms is crucial for evaluating therapeutic efficacy.

Conclusions:

• Raising HDL-C levels presents a promising strategy for CHD prevention, supported by observational data and early trials.
• Ongoing large-scale clinical trials are essential to definitively establish the role of HDL-C-raising therapies in patient management.
• A comprehensive understanding of HDL biology is key to guiding future therapeutic development and clinical application.